Morgan Stanley analyst Craig Hettenbach initiated coverage of Hims & Hers with an Overweight rating and $42 price target The firm views Hims & Hers as a “compelling compounding investment” and estimates annual revenue growth of 30% through 2026, “building on very strong growth” of 80% per annum in the last three years. The company has established itself with one of the stronger track records spanning the domains of digital health and direct-to-consumer, the analyst tells investors in a research note. Morgan Stanley believes Hims & Hers has a scalable technology platform.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Ro, Lilly partnership creates volatility for Hims & Hers shares, says Leerink
- BofA views news of Lilly selling Zepbound through Ro as ‘mixed’ for Hims & Hers
- ADA advises doctors, patients not to use compounded GLP-1s
- Hims & Hers price target raised to $38 from $28 at Canaccord
- Trump Weekly: Autos, retail, restaurant sectors brace for import tariffs